Payment overview · 2025
General Payments
$228.47
11 reported records · 5 companies
Healthcare provider profile · identity verified
Ian Patrick Coe, MD
Allopathic & Osteopathic Physicians|Family Medicine · REEDSPORT, OR · NPI 1902469208
Verified facts
What the public records show
CMS Open Payments records show Ian Patrick Coe, MD received $228.47 in general payments during 2025 across 11 reported records.
Edwards Lifesciences Corporation accounted for 32.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Entresto by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 94 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $73.74 | 32.3% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $55.08 | 24.1% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $49.33 | 21.6% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $28.64 | 12.5% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $21.68 | 9.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $228.47 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Edwards SAPIEN 3 Ultra Transcatheter Heart Valve Normalized: edwards sapien 3 ultra transcatheter heart valve |
Device | Edwards Lifesciences Corporation | $50.10 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $49.33 | 3 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $39.40 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $39.40 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $39.40 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $28.64 | 1 | 2025 |
Source payment records
|
|||||
| SAPIEN 3 Ultra RESILIA Normalized: sapien 3 ultra resilia |
Device | Edwards Lifesciences Corporation | $23.64 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $21.68 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $15.68 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
94 | 22 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 520 | 161 |
| Losartan Potassium | Losartan Potassium | 365 | 107 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 314 | 52 |
| Gabapentin | Gabapentin | 310 | 81 |
| Amlodipine Besylate | Amlodipine Besylate | 283 | 92 |
| Lisinopril | Lisinopril | 266 | 77 |
| Levothyroxine Sodium | Levothyroxine Sodium | 258 | 73 |
| Omeprazole | Omeprazole | 250 | 64 |
| Metoprolol Succinate | Metoprolol Succinate | 216 | 65 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 209 | 72 |
| Furosemide | Furosemide | 182 | 47 |
| Metformin Hcl | Metformin Hcl | 181 | 50 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 156 | 42 |
| Duloxetine Hcl | Duloxetine Hcl | 126 | 34 |
| Trazodone Hcl | Trazodone Hcl | 126 | 41 |
| Meloxicam | Meloxicam | 124 | 42 |
| Tamsulosin Hcl | Tamsulosin Hcl | 123 | 39 |
| Pantoprazole Sodium | Pantoprazole Sodium | 120 | 38 |
| Hydrochlorothiazide | Hydrochlorothiazide | 116 | 35 |
| Pregabalin | Pregabalin | 115 | 22 |
| Metoprolol Tartrate | Metoprolol Tartrate | 104 | 34 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 102 | 29 |
| Simvastatin | Simvastatin | 99 | 28 |
| Eliquis | Apixaban | 94 | 22 |
| Potassium Chloride | Potassium Chloride | 90 | 25 |
| Fluticasone Propionate | Fluticasone Propionate | 87 | 23 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 82 | 15 |
| Tizanidine Hcl | Tizanidine Hcl | 81 | 24 |
| Spironolactone | Spironolactone | 77 | 21 |
| Pravastatin Sodium | Pravastatin Sodium | 74 | 21 |
| Xarelto | Rivaroxaban | 74 | 21 |
| Tramadol Hcl | Tramadol Hcl | 73 | 20 |
| Ozempic | Semaglutide | 70 | 13 |
| Bupropion Xl | Bupropion Hcl | 69 | 20 |
| Metformin Hcl Er | Metformin Hcl | 69 | 21 |
| Carvedilol | Carvedilol | 67 | 18 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 65 | 28 |
| Trulicity | Dulaglutide | 65 | 12 |
| Famotidine | Famotidine | 62 | 19 |
| Prednisone | Prednisone | 60 | 29 |
| Celecoxib | Celecoxib | 58 | 24 |
| Fluoxetine Hcl | Fluoxetine Hcl | 58 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 58 | 23 |
| Montelukast Sodium | Montelukast Sodium | 58 | 19 |
| Allopurinol | Allopurinol | 55 | 18 |
| Jardiance | Empagliflozin | 52 | 18 |
| Quetiapine Fumarate | Quetiapine Fumarate | 52 | 15 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 47 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 47 | 19 |
| Alendronate Sodium | Alendronate Sodium | 46 | 14 |
| Levetiracetam | Levetiracetam | 46 | suppressed |
| Atenolol | Atenolol | 45 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 45 | 15 |
| Synthroid | Levothyroxine Sodium | 45 | 12 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 44 | 13 |
| Propranolol Hcl Er | Propranolol Hcl | 44 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 44 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 43 | 15 |
| Diclofenac Sodium | Diclofenac Sodium | 43 | 12 |
| Oxycodone Hcl | Oxycodone Hcl | 43 | 11 |
| Buspirone Hcl | Buspirone Hcl | 42 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 42 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 41 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 41 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 41 | suppressed |
| Ezetimibe | Ezetimibe | 40 | 12 |
| Glipizide Er | Glipizide | 38 | suppressed |
| Lorazepam | Lorazepam | 38 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 37 | suppressed |
| Glipizide | Glipizide | 37 | 11 |
| Methocarbamol | Methocarbamol | 37 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 36 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 35 | 11 |
| Mirtazapine | Mirtazapine | 35 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 35 | 11 |
| Estradiol | Estradiol | 33 | 11 |
| Ibuprofen | Ibuprofen | 33 | 11 |
| Advair Hfa | Fluticasone Propion/Salmeterol | 30 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 30 | suppressed |
| Lovastatin | Lovastatin | 30 | suppressed |
| Mounjaro | Tirzepatide | 30 | suppressed |
| Ondansetron Odt | Ondansetron | 29 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 29 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 28 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 28 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 28 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 28 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 27 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 26 | suppressed |
| Acyclovir | Acyclovir | 25 | suppressed |
| Finasteride | Finasteride | 25 | suppressed |
| Nystatin | Nystatin | 25 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 25 | suppressed |
| Alprazolam | Alprazolam | 24 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 24 | suppressed |
| Clotrimazole | Clotrimazole | 24 | suppressed |
| Lamotrigine | Lamotrigine | 24 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 24 | suppressed |
| Baclofen | Baclofen | 22 | suppressed |
| Repatha Sureclick | Evolocumab | 21 | suppressed |
| Testosterone | Testosterone | 21 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 20 | suppressed |
| Latanoprost | Latanoprost | 20 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 19 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 19 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 19 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 19 | suppressed |
| Clonazepam | Clonazepam | 18 | suppressed |
| Diazepam | Diazepam | 18 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 18 | 17 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 17 | suppressed |
| Cephalexin | Cephalexin | 17 | suppressed |
| Entresto | Sacubitril/Valsartan | 17 | suppressed |
| Sucralfate | Sucralfate | 17 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 16 | suppressed |
| Methotrexate | Methotrexate Sodium | 16 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 16 | suppressed |
| Nitroglycerin | Nitroglycerin | 16 | 12 |
| Pioglitazone Hcl | Pioglitazone Hcl | 16 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 16 | suppressed |
| Calcitriol | Calcitriol | 15 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 15 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 15 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 15 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Mupirocin | Mupirocin | 14 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 14 | suppressed |
| Dayvigo | Lemborexant | 13 | suppressed |
| Levemir Flexpen | Insulin Detemir | 13 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 13 | suppressed |
| Nystop | Nystatin | 13 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 12 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Fentanyl | Fentanyl | 12 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 12 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 12 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 12 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 12 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Bumetanide | Bumetanide | 11 | suppressed |
| Glimepiride | Glimepiride | 11 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 11 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $228.47 · 11 records | Edwards Lifesciences Corporation | ABRYSVO, COMIRNATY, EVENITY, Edwards SAPIEN 3 Ultra Transcatheter Heart Valve, LEQVIO, PAXLOVID, PREVNAR 20, SAPIEN 3 Ultra RESILIA, The Cologuard Plus Collection Kit | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Novartis Pharmaceuticals Corporation?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error